Please login to the form below

Not currently logged in
Email:
Password:

Avanir Pharmaceuticals

This page shows the latest Avanir Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Avanir to co-promote Merck's diabetes drugs in the US

Avanir to co-promote Merck's diabetes drugs in the US

Merck &Co and Avanir Pharmaceuticals have entered an agreement to co-promote Merck's portfolio of sitagliptin-based diabetes products in the US. ... Rohan Palekar, chief commercial officer at Avanir, confirmed Merck's ambitions in the area.

Latest news

  • Genzyme appoints MS and rare diseases business leaders

    He joins Genzyme from Avanir Pharmaceuticals, where he was the chief commercial officer, leading all of the company's commercial activities.

  • Coronary conundrums

    Moderate to severe chronic pain. US. Dextromethorphan/quinidine. Nuedexta (Avanir Pharmaceuticals). Pseudobulbar affect. ... US. Lurasidone. Latuda (Sunovion Pharmaceuticals). Schizophrenia. US an Puerto Rico. Paracetamol.

  • Pharma news in brief

    AZ buys into new cholesterol treatment. AstraZeneca has agreed to pay US biotech firm Avanir Pharmaceuticals up to £195m in cash and conditional milestones in a licensing deal for cardiovascular products, ... including Avanir's reverse cholesterol

  • British Bulldog

    AZ is also developing, in conjunction with the US Avanir Pharmaceuticals, a new type of cholesterol-lowering pill. ... Another pharma group in the FTSE 100 index, Shire Pharmaceuticals, also moved smartly higher thanks to the weak pound and a

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 9, 500. Avanir Pharmaceuticals / Otsuka Pharmaceutical. Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect. ... Research collaboration, options to license. 125. †† Ariad Pharmaceuticals / Otsuka

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga. ... JV. Speciality pharmaceuticals. 200. Merck &Co /. Avanir Pharmaceuticals. Co-promotion. Januvia, Janumet and Jamumet XR in nursing homes.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    208. Talon Therapeutics / Spectrum Pharmaceuticals. Acquisition. Haemato-oncology portfolio, Marqibo for leukaemia (FDA approved). ... 121. ‡ Optinose / Avanir Pharmaceuticals. Licence. Breath Powered intranasal sumatriptan for migraine (p3).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics